• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胶质瘤的识别与管理

Recognition and management of gliomas.

作者信息

Kaba S E, Kyritsis A P

机构信息

Department of Neurology, University of Arkansas for Medical Sciences, Little Rock, USA.

出版信息

Drugs. 1997 Feb;53(2):235-44. doi: 10.2165/00003495-199753020-00004.

DOI:10.2165/00003495-199753020-00004
PMID:9028743
Abstract

Gliomas are the most frequent primary brain tumours. They include astrocytic gliomas, oligodendrocytic gliomas, ependymomas and gliomas with mixed cell populations. Each glioma type consists of both low-grade and malignant atypical varieties. The low-grade tumours occur predominantly in children and young adults, and the malignant forms in older people. The presenting symptoms are epileptic seizures, headache and mental confusion. Focal neurological symptoms and findings, such as hemiparesis, are mostly associated with the malignant forms. Magnetic resonance imaging (MRI) scan of the brain with and without gadolinium contrast demonstrates the tumour. However, stereotactic biopsy or surgical resection is necessary to obtain the correct pathological diagnosis, except for diffuse pontine astrocytomas, which have an unmistakeable imaging appearance and for which biopsy has substantial risks. Treatment depends on the pathological diagnosis. Complete surgical resection may be curative for low-grade tumours. Postoperative radiotherapy is recommended for partially resected tumours. Most malignant gliomas require aggressive combination therapy with radiotherapy and chemotherapy after maximal surgery. The standard initial regimens are nitrosourea-based chemotherapies, such as carmustine alone, a combination of procarbazine, lomustine and vincristine, or a combination of thioguanine, procarbazine, lomustine and hydroxycarbamide (hydroxyurea). Unfortunately, the prognosis of malignant gliomas is generally poor despite aggressive treatment, because of their infiltrative nature and high relapse rate.

摘要

神经胶质瘤是最常见的原发性脑肿瘤。它们包括星形细胞胶质瘤、少突胶质细胞胶质瘤、室管膜瘤以及具有混合细胞群的胶质瘤。每种神经胶质瘤类型都包括低级别和恶性非典型变种。低级别肿瘤主要发生在儿童和年轻人中,而恶性形式则多见于老年人。出现的症状有癫痫发作、头痛和精神错乱。局灶性神经症状和体征,如偏瘫,大多与恶性形式相关。脑部磁共振成像(MRI)扫描,无论有无钆造影剂,都能显示肿瘤。然而,除了具有明确影像学表现且活检有很大风险的弥漫性脑桥星形细胞瘤外,需要进行立体定向活检或手术切除以获得正确的病理诊断。治疗取决于病理诊断。完整的手术切除可能治愈低级别肿瘤。对于部分切除的肿瘤,建议术后放疗。大多数恶性神经胶质瘤在最大限度手术切除后需要放疗和化疗的积极联合治疗。标准的初始方案是以亚硝基脲为基础的化疗,如单独使用卡莫司汀、丙卡巴肼、洛莫司汀和长春新碱的联合方案,或硫鸟嘌呤、丙卡巴肼、洛莫司汀和羟基脲(羟基尿素)的联合方案。不幸的是,尽管进行了积极治疗,但由于恶性神经胶质瘤具有浸润性和高复发率,其预后通常很差。

相似文献

1
Recognition and management of gliomas.胶质瘤的识别与管理
Drugs. 1997 Feb;53(2):235-44. doi: 10.2165/00003495-199753020-00004.
2
Pediatric glial tumors.小儿神经胶质瘤
Curr Treat Options Oncol. 2001 Dec;2(6):529-36. doi: 10.1007/s11864-001-0074-9.
3
Brainstem gliomas in adults: prognostic factors and classification.成人脑干胶质瘤:预后因素与分类
Brain. 2001 Dec;124(Pt 12):2528-39. doi: 10.1093/brain/124.12.2528.
4
Central nervous system gliomas.中枢神经系统胶质瘤
Crit Rev Oncol Hematol. 2017 May;113:213-234. doi: 10.1016/j.critrevonc.2017.03.021. Epub 2017 Mar 22.
5
Chemotherapy for malignant gliomas.恶性胶质瘤的化疗
Oncology (Williston Park). 1993 Sep;7(9):93-100; discussion 103, 106.
6
Practical guidelines for the treatment of malignant gliomas.恶性胶质瘤治疗实用指南。
West J Med. 1998 Feb;168(2):114-20.
7
Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas.儿童高级别胶质瘤和弥漫性脑桥内在型胶质瘤。
J Child Neurol. 2009 Nov;24(11):1409-17. doi: 10.1177/0883073809338960. Epub 2009 Jul 28.
8
Low-grade gliomas -- current concepts.低级别胶质瘤——当前概念
Zentralbl Neurochir. 2006 May;67(2):55-66. doi: 10.1055/s-2006-933408.
9
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review.成人脑胶质瘤和其他原发性脑恶性肿瘤:综述。
JAMA. 2023 Feb 21;329(7):574-587. doi: 10.1001/jama.2023.0023.
10
[Pattern of care of high-grade gliomas].[高级别胶质瘤的治疗模式]
Rev Prat. 2006 Oct 31;56(16):1779-86.

引用本文的文献

1
The Role of Curcumin in Cancer: A Focus on the PI3K/Akt Pathway.姜黄素在癌症中的作用:聚焦于PI3K/Akt信号通路。
Cancers (Basel). 2024 Apr 18;16(8):1554. doi: 10.3390/cancers16081554.
2
Exosomal circZNF800 Derived from Glioma Stem-like Cells Regulates Glioblastoma Tumorigenicity via the PIEZO1/Akt Axis.外泌体环状 ZNF800 来源于神经胶质瘤干细胞,通过 PIEZO1/Akt 轴调节神经胶质瘤的致瘤性。
Mol Neurobiol. 2024 Sep;61(9):6556-6571. doi: 10.1007/s12035-024-04002-0. Epub 2024 Feb 7.
3
Nuclear Medicine and Cancer Theragnostics: Basic Concepts.

本文引用的文献

1
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.6-硫鸟嘌呤、丙卡巴肼、洛莫司汀和羟基脲联合用于复发性恶性胶质瘤患者。
Neurosurgery. 1996 Nov;39(5):921-6. doi: 10.1097/00006123-199611000-00006.
2
Resolution of recurrent malignant ganglioglioma after treatment with cis-retinoic acid.顺式维甲酸治疗后复发性恶性神经节胶质瘤消退
J Neurooncol. 1996 Oct;30(1):55-60. doi: 10.1007/BF00177443.
3
Advances in chemotherapy for brain tumors.脑肿瘤化疗的进展
核医学与癌症诊疗学:基本概念
Diagnostics (Basel). 2023 Sep 26;13(19):3064. doi: 10.3390/diagnostics13193064.
4
Exosomal circRNAs as promising liquid biopsy biomarkers for glioma.外泌体 circRNAs 作为胶质瘤有前途的液体活检生物标志物。
Front Immunol. 2023 Apr 14;14:1039084. doi: 10.3389/fimmu.2023.1039084. eCollection 2023.
5
Characteristics of F-FDG and F-FDOPA PET in an 8-year-old neutered male Yorkshire Terrier dog with glioma: long-term chemotherapy using hydroxyurea plus imatinib with prednisolone and immunoreactivity for PDGFR-β and LAT1.8 岁已绝育雄性约克夏梗犬脑胶质瘤的 F-FDG 和 F-FDOPA PET 特征:用羟基脲联合伊马替尼、泼尼松进行长期化疗及 PDGFR-β和 LAT1 的免疫反应性。
Vet Q. 2021 Dec;41(1):163-171. doi: 10.1080/01652176.2021.1906466.
6
Excited State Lifetimes of Sulfur-Substituted DNA and RNA Monomers Probed Using the Femtosecond Fluorescence Up-Conversion Technique.使用飞秒荧光上转换技术探测硫取代的 DNA 和 RNA 单体的激发态寿命。
Molecules. 2020 Jan 29;25(3):584. doi: 10.3390/molecules25030584.
7
Symptomatic diagnosis of cancer of the brain and central nervous system in primary care: a systematic review.基层医疗中脑与中枢神经系统癌症的症状诊断:一项系统综述
Fam Pract. 2015 Dec;32(6):618-23. doi: 10.1093/fampra/cmv075. Epub 2015 Oct 14.
8
Bradykinin promotes the chemotactic invasion of primary brain tumors.缓激肽促进原发性脑肿瘤的趋化浸润。
J Neurosci. 2011 Mar 30;31(13):4858-67. doi: 10.1523/JNEUROSCI.3825-10.2011.
9
The correlation between 1H MRS choline concentrations and MR diffusion trace values in human brain tumors.人脑肿瘤中1H磁共振波谱胆碱浓度与磁共振扩散示踪值之间的相关性。
MAGMA. 2009 Feb;22(1):19-31. doi: 10.1007/s10334-008-0150-2. Epub 2008 Oct 25.
10
RNAi-mediated inhibition of MSP58 decreases tumour growth, migration and invasion in a human glioma cell line.RNAi 介导的 MSP58 抑制降低了人神经胶质瘤细胞系中的肿瘤生长、迁移和侵袭。
J Cell Mol Med. 2009 Nov-Dec;13(11-12):4608-22. doi: 10.1111/j.1582-4934.2008.00499.x.
Neurol Clin. 1995 Nov;13(4):795-812.
4
Intracranial ependymoma long term outcome, patterns of failure.颅内室管膜瘤的长期预后及复发模式。
J Neurooncol. 1993 Feb;15(2):125-31. doi: 10.1007/BF01053933.
5
Brainstem glioma: I. Pathology, clinical features, and therapy.脑干胶质瘤:I. 病理学、临床特征及治疗
J Child Neurol. 1993 Apr;8(2):112-28. doi: 10.1177/088307389300800203.
6
Epidemiology, cytogenetics, and molecular biology of brain tumors.脑肿瘤的流行病学、细胞遗传学和分子生物学
Curr Opin Oncol. 1993 May;5(3):474-80. doi: 10.1097/00001622-199305000-00006.
7
Chemotherapy for pilocytic astrocytomas.毛细胞型星形细胞瘤的化疗
Cancer. 1993 May 15;71(10):3165-72. doi: 10.1002/1097-0142(19930515)71:10<3165::aid-cncr2820711044>3.0.co;2-n.
8
A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study.一项关于低级别胶质瘤不完全切除术后放疗与放疗联合洛莫司汀对比的随机试验:西南肿瘤协作组研究
J Neurosurg. 1993 Jun;78(6):909-14. doi: 10.3171/jns.1993.78.6.0909.
9
The treatment of anaplastic oligodendrogliomas and mixed gliomas.间变性少突胶质细胞瘤和混合性胶质瘤的治疗
Neurosurgery. 1993 Mar;32(3):365-70; discussion 371. doi: 10.1227/00006123-199303000-00005.
10
Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.成人恶性胶质瘤辅助化疗与非辅助化疗的放射治疗荟萃分析。
Cancer. 1993 Apr 15;71(8):2585-97. doi: 10.1002/1097-0142(19930415)71:8<2585::aid-cncr2820710825>3.0.co;2-s.